Your Location:
Home >
Browse articles >
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies
- “In the field of liver cancer treatment, researchers have made significant progress. They found that radiofrequency ablation (RFA) treatment upregulated MELK expression, and MELK inhibition promoted RFA efficacy by immunogenic cell death and the antitumor response. Targeting MELK via RGD-LNPs provides new insight into improving RFA efficacy in HCC clinical treatment and combating the malignant progression of liver cancer.”
- Military Medical Research Vol. 12, Issue 7, Pages: 1046-1064(2025)
DOI: 10.1186/s40779-024-00588-7
Scan QR Code
AI Introduction
Full Text(HTML)
Figs( 8 ) Tabs( 0 )
References
Publication Info
Metrics
48
Views
36
Downloads
0
CSCD
Alert me when the article has been cited
Submit
Tools
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Related Articles
Immune microenvironment dynamics in pregnant patients with concomitant autoimmune diseases: mechanisms, challenges, and clinical significance
Role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity
mRNA vaccine development for cholangiocarcinoma: a precise pipeline
Engineering of functional auditory neurons from human induced pluripotent stem cells
Maladaptive reorganization of mediodorsal thalamus as a central mechanism in neuropathic pain-related sleep disorders
Related Author
Ji-Xin Zhong
Xiao-Quan Rao
Ying-Ying Wei
Zachary Braunstein
Quan Gong
Shun-Ping Lin
Chen-Xi Yang
Jun Chen
Related Institution
Key Laboratory of Vascular Aging (HUST), Ministry of Education
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, the Ohio State University Wexner Medical Center
Department of Immunology, School of Medicine, Yangtze University
Fujian Institute of Clinical Immunology

